| [1] |
ZHENG RS, SUN KX, ZHANG SW, et al. Report of cancer epidemiology in China, 2015[J]. Chin J Oncol, 2019, 41(1): 19-28. (in Chinese)
郑荣寿, 孙可欣, 张思维, 等. 2015年中国恶性肿瘤流行情况分析[J]. 中华肿瘤杂志, 2019, 41(1): 19-28.
|
| [2] |
TORRE LA, BRAY F, SIEGEL RL, et al. Global cancer statistics, 2012[J]. CA Cancer J Clin, 2015, 65(2): 87-108. DOI: 10.3322/caac.21262 |
| [3] |
Bureau of Medical Administration, National Health Commission of the People's Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition)[J]. J Clin Hepatol, 2020, 36(2): 277-292. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2020.02.007 |
| [4] |
MAZZAFERRO V, REGALIA E, DOCI R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis[J]. N Engl J Med, 1996, 334(11): 693-699. DOI: 10.1056/NEJM199603143341104 |
| [5] |
YAO FY, FERRELL L, BASS NM, et al. Liver transplantation for hepatocellular carcinoma: Expansion of the tumor size limits does not adversely impact survival[J]. Hepatology, 2001, 33(6): 1394-1403. DOI: 10.1053/jhep.2001.24563 |
| [6] |
ZHENG SS, XU X, WU J, et al. Liver transplantation for hepatocellular carcinoma: Hangzhou experiences[J]. Transplantation, 2008, 85(12): 1726-1732. DOI: 10.1097/TP. 0b013e31816b67e4 |
| [7] |
YAO FY, MEHTA N, FLEMMING J, et al. Downstaging of hepatocellular cancer before liver transplant: Long-term outcome compared to tumors within Milan criteria[J]. Hepatology, 2015, 61(6): 1968-1977. DOI: 10.1002/hep.27752 |
| [8] |
Organ Transplantation Branch, Chinese Medical Doctor Association; Chinese Society of Organ Transplantation, Chinese Medical Association. The Chinese clinical practice guideline on liver transplantation for hepatocellular carcinoma (2018)[J]. J Clin Hepatol, 2019, 35(2): 275-280. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.02.008 |
| [9] |
BRUIX J, SHERMAN M, LLOVET JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver[J]. J Hepatol, 2001, 35(3): 421-430. DOI: 10.1016/S0168-8278(01)00130-1 |
| [10] |
European Association for the Study of the Liver, European Organisation for Research and Treatment of Cancer. EASL-EORTC clinical practice guidelines: Management of hepatocellular carcinoma[J]. J Hepatol, 2012, 56(4): 908-943. DOI: 10.1016/j.jhep.2011.12.001 |
| [11] |
CLAVIEN PA, LESURTEL M, BOSSUYT PM, et al. Recommendations for liver transplantation for hepatocellular carcinoma: An international consensus conference report[J]. Lancet Oncol, 2012, 13(1): e11-e22. DOI: 10.1016/S1470-2045(11)70175-9 |
| [12] |
WANG H, CHEN G, GAO HJ, et al. The value of DEB-TACE as down-stage therapy for hepatocellular carcinoma before liver transplantation[J]. Chin J Gen Surg, 2019, 34(5): 410-412. (in Chinese) DOI: 10.3760/cma.j.issn.1007-631X.2019.05.009 |
| [13] |
BOUCHARD-FORTIER A, LAPOINTE R, PERREAULT P, et al. Transcatheter arterial chemoembolization of hepatocellular carcinoma as a bridge to liver transplantation: A retrospective study[J]. Int J Hepatol, 2011, 2011: 974514.
|
| [14] |
CHOI SH, SEONG J. Strategic application of radiotherapy for hepatocellular carcinoma[J]. Clin Mol Hepatol, 2018, 24(2): 114-134. DOI: 10.3350/cmh.2017.0073 |
| [15] |
CHONG JU, CHOI GH, HAN DH, et al. Downstaging with localized concurrent chemoradiotherapy can identify optimal surgical candidates in hepatocellular carcinoma with portal vein tumor thrombus[J]. Ann Surg Oncol, 2018, 25(11): 3308-3315. DOI: 10.1245/s10434-018-6653-9 |
| [16] |
ASSALINO M, TERRAZ S, GRAT M, et al. Liver transplantation for hepatocellular carcinoma after successful treatment of macrovascular invasion - a multi-center retrospective cohort study[J]. Transpl Int, 2020, 33(5): 567-575. DOI: 10.1111/tri.13586 |
| [17] |
Chinese Society of Liver Cancer, Chinese Medical Doctor Association. Chinese expert consensus on multidisciplinary diagnosis and treatment of hepatocellular carcinoma with portal vein tumor thrombus (2018)[J]. J Clin Hepatol, 2019, 35(4): 737-743. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2019.04.008 |
| [18] |
PRACHT M, EDELINE J, LENOIR L, et al. Lobar hepatocellular carcinoma with ipsilateral portal vein tumor thrombosis treated with yttrium-90 glass microsphere radioembolization: Preliminary results[J]. Int J Hepatol, 2013, 2013: 827649.
|
| [19] |
CHENG AL, KANG YK, CHEN Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: A phase Ⅲ randomised, double-blind, placebo-controlled trial[J]. Lancet Oncol, 2009, 10(1): 25-34. DOI: 10.1016/S1470-2045(08)70285-7 |
| [20] |
IKEDA M, OKUSAKA T, MITSUNAGA S, et al. Safety and pharmacokinetics of lenvatinib in patients with advanced hepatocellular carcinoma[J]. Clin Cancer Res, 2016, 22(6): 1385-1394. DOI: 10.1158/1078-0432.CCR-15-1354 |
| [21] |
EL-KHOUEIRY AB, SANGRO B, YAU T, et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): An open-label, non-comparative, phase 1/2 dose escalation and expansion trial[J]. Lancet, 2017, 389(10088): 2492-2502. DOI: 10.1016/S0140-6736(17)31046-2 |
| [22] |
ZHU AX, FINN RS, EDELINE J, et al. Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): A non-randomised, open-label phase 2 trial[J]. Lancet Oncol, 2018, 19(7): 940-952. DOI: 10.1016/S1470-2045(18)30351-6 |
| [23] |
IRTAN S, CHOPIN-LALY X, RONOT M, et al. Complete regression of locally advanced hepatocellular carcinoma induced by sorafenib allowing curative resection[J]. Liver Int, 2011, 31(5): 740-743. DOI: 10.1111/j.1478-3231.2010.02441.x |
| [24] |
VAGEFI PA, HIROSE R. Downstaging of hepatocellular carcinoma prior to liver transplant: Is there a role for adjuvant sorafenib in locoregional therapy?[J]. J Gastrointest Cancer, 2010, 41(4): 217-220. DOI: 10.1007/s12029-010-9163-y |
| [25] |
JENG KS, HUANG CC, LIN CC, et al. Liver transplantation after downstagings of ruptured advanced hepatocellular carcinoma in cirrhotic liver: Is it advisable? A case report[J]. Transplant Proc, 2019, 51(5): 1468-1471. DOI: 10.1016/j.transproceed.2019.01.125 |
| [26] |
HU B, YANG XB, SANG XT. Liver graft rejection following immune checkpoint inhibitors treatment: A review[J]. Med Oncol, 2019, 36(11): 94. DOI: 10.1007/s12032-019-1316-7 |
| [27] |
NORDNESS MF, HAMEL S, GODFREY CM, et al. Fatal hepatic necrosis after nivolumab as a bridge to liver transplant for HCC: Are checkpoint inhibitors safe for the pretransplant patient?[J]. Am J Transplant, 2020, 20(3): 879-883. DOI: 10.1111/ajt.15617 |
| [28] |
KITTAI AS, OLDHAM H, CETNAR J, et al. Immune checkpoint inhibitors in organ transplant patients[J]. J Immunother, 2017, 40(7): 277-281. DOI: 10.1097/CJI.0000000000000180 |
| [29] |
COHEN GS, BLACK M. Multidisciplinary management of hepatocellular carcinoma: A model for therapy[J]. J Multidiscip Healthc, 2013, 6: 189-195.
|
| [30] |
SIDDIQUE O, YOO ER, PERUMPAIL RB, et al. The importance of a multidisciplinary approach to hepatocellular carcinoma[J]. J Multidiscip Healthc, 2017, 10: 95-100. DOI: 10.2147/JMDH.S128629 |
| [31] |
TRIOLO M, SANGIOVANNI A, LA MURA V, et al. Multimodality treatment of hepatocellular carcinoma: How field practice complies with international recommendations[J]. Dig Liver Dis, 2016, 48(Suppl 1): e26.
|
DownLoad: